The shares of this pharmaceutical company gained up to 1.5 percent after the company obtained product approval in South Africa.
With a market capitalization of Rs 923.48 crore, the shares of Kwality Pharmaceuticals Ltd were trading at Rs 890.00 per share, increasing around 1.16 percent as compared to the previous closing price of Rs 879.80 apiece.
Reason for Rise:-
The company shares have seen positive movement after Kwality Pharmaceuticals Ltd obtained product approval in South Africa (SAHPRA) for its prominent oncology oral solid dosage (OSD) product, Tamoxifen 20mg Tablet, through a site transfer process.
Moreover, this approval is a crucial step in increasing the availability of this key therapy, which is essential in the treatment of hormone receptor-positive breast cancer. It demonstrates the company’s continuous commitment to providing high-quality, affordable cancer medicines to patients in critical markets.
Financial performance:-
Looking forward to the company’s financial condition, revenue increased slightly by 29 percent from Rs 69.65 crore in Q2FY24 to Rs 90.03 crore in Q2FY25, net profit increased by 36 percent from Rs 6.22 crore to Rs 8.46 crore.
Ratio analysis:-
The company’s profitability measures show an incline in return on equity (RoE) from 9.69 percent in FY 22-23 to 10.65 percent in FY 23-24, while, during the same period return on capital employed (RoCE) decreased from 21.13 percent to 20.04 percent. In contrast, the net profit margin (NPM) was 7.68 percent in fiscal year 23-24.
Shareholding pattern:-
In the company’s recent shareholding pattern, the Promoters of the company own 54.82 percent while Retail shareholders own a 45.15 percent stake in the company and domestic institutional Investors own a 0.02 percent stake.
Company profile:-
Kwality Pharmaceuticals Limited is a manufacturer of finished pharmaceutical formulations in a dosage form. The Company is engaged in the business of manufacturers, buyers, and sellers of and dealers in all kinds of drug intermediates, chemicals, extracts, alkaloids, and other pharmaceutical goods.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
